Treatment research progress of cirrhosis of the liver decompensation period, the splenic function and thrombocytopenia after hepatitis C

VernacularTitle:丙型肝炎后肝硬化失代偿期、脾功能亢进、血小板减少的治疗研究进展
Author: Longzhen SHI ; Ping XIAO ; Liting ZHANG
Keywords: Hepatitis C; Cirrhosis of the liver; The splenic function; Sustained virological response; Liver transplantation; The spleen cut method; Direct antiviral drugs
From: Clinical Medicine of China 2017;33(6):568-572
CountryChina
Language:Chinese
Abstract: HCV-related decompensated cirrhos,hypersplenism,thrombocytopenia,which not only affect the standard antiviral therapy,fail to achieve the sustained virological response(SVR),but also increase the risk of infection and bleeding.The only successful option is liver transplantation (LT),but the recurrence of HCV after LT remains to be resolved.The patients of HCV genotype 2 are suitable for splenectomy and antiviral therapy following splenectomy,which can achieved a higher SVR and reversed cirrhosis.As an effective alternative to splenectomy,the partial splenic embolization (PSE) can improve the changes of portal hemodynamics and reduce the sequelae of portal hypertension.The appearance of direct antiviral drugs (DAAs)has bring hope for those with decompensated cirrhos and whom IFN is contraindicated or tolerated poorly,those who are waiting for LT or with recurrence of hepatitis C after LT.The treatment of patients with decompensated cirrhos is as follows.